Compare Lupin Ltd with - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LUPIN vs ALKEM LABORATORIES - Comparison Results

LUPIN     Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    LUPIN ALKEM LABORATORIES LUPIN/
ALKEM LABORATORIES
 
P/E (TTM) x 48.4 - - View Chart
P/BV x 2.5 6.6 37.3% View Chart
Dividend Yield % 0.0 0.7 -  

Financials

 LUPIN   ALKEM LABORATORIES
EQUITY SHARE DATA
    LUPIN
Mar-19
ALKEM LABORATORIES
Mar-16
LUPIN/
ALKEM LABORATORIES
5-Yr Chart
Click to enlarge
High Rs9861,589 62.1%   
Low Rs7201,232 58.5%   
Sales per share (Unadj.) Rs369.5417.5 88.5%  
Earnings per share (Unadj.) Rs13.456.3 23.8%  
Cash flow per share (Unadj.) Rs37.464.7 57.8%  
Dividends per share (Unadj.) Rs012.70 0.0%  
Dividend yield (eoy) %00.9 0.0%  
Book value per share (Unadj.) Rs303.7292.9 103.7%  
Shares outstanding (eoy) m452.49119.57 378.4%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.33.4 68.3%   
Avg P/E ratio x63.625.1 254.0%  
P/CF ratio (eoy) x22.821.8 104.7%  
Price / Book Value ratio x2.84.8 58.3%  
Dividend payout %022.6 0.0%   
Avg Mkt Cap Rs m386,064168,653 228.9%   
No. of employees `00017.7NA-   
Total wages/salary Rs m31,5139,171 343.6%   
Avg. sales/employee Rs Th9,453.8NM-  
Avg. wages/employee Rs Th1,782.0NM-  
Avg. net profit/employee Rs Th343.0NM-  
INCOME DATA
Net Sales Rs m167,18249,915 334.9%  
Other income Rs m3,6401,645 221.3%   
Total revenues Rs m170,82251,561 331.3%   
Gross profit Rs m28,8228,482 339.8%  
Depreciation Rs m10,8501,006 1,078.8%   
Interest Rs m3,078671 459.0%   
Profit before tax Rs m18,5348,451 219.3%   
Minority Interest Rs m-89-114 78.5%   
Prior Period Items Rs m380-   
Extraordinary Inc (Exp) Rs m-3,4000-   
Tax Rs m9,0171,606 561.5%   
Profit after tax Rs m6,0666,731 90.1%  
Gross profit margin %17.217.0 101.5%  
Effective tax rate %48.719.0 256.0%   
Net profit margin %3.613.5 26.9%  
BALANCE SHEET DATA
Current assets Rs m138,53627,062 511.9%   
Current liabilities Rs m61,29915,324 400.0%   
Net working cap to sales %46.223.5 196.5%  
Current ratio x2.31.8 128.0%  
Inventory Days Days8467 126.0%  
Debtors Days Days11241 272.4%  
Net fixed assets Rs m127,51612,610 1,011.3%   
Share capital Rs m905239 378.5%   
"Free" reserves Rs m136,51734,490 395.8%   
Net worth Rs m137,42235,027 392.3%   
Long term debt Rs m66,4171,212 5,481.8%   
Total assets Rs m279,49454,387 513.9%  
Interest coverage x7.013.6 51.6%   
Debt to equity ratio x0.50 1,397.2%  
Sales to assets ratio x0.60.9 65.2%   
Return on assets %3.313.6 24.0%  
Return on equity %4.419.2 23.0%  
Return on capital %8.924.9 35.8%  
Exports to sales %012.9 0.0%   
Imports to sales %03.1 0.0%   
Exports (fob) Rs mNA6,461 0.0%   
Imports (cif) Rs mNA1,540 0.0%   
Fx inflow Rs m59,4146,563 905.2%   
Fx outflow Rs m22,2823,012 739.8%   
Net fx Rs m37,1323,552 1,045.5%   
CASH FLOW
From Operations Rs m16,6607,259 229.5%  
From Investments Rs m-32,8251,864 -1,760.8%  
From Financial Activity Rs m7,441-9,273 -80.2%  
Net Cashflow Rs m-8,724-150 5,815.8%  

Share Holding

Indian Promoters % 46.6 66.9 69.7%  
Foreign collaborators % 0.2 0.0 -  
Indian inst/Mut Fund % 11.3 33.1 34.1%  
FIIs % 31.9 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 10.1 0.0 -  
Shareholders   98,259 68,381 143.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare LUPIN With:   TTK HEALTHCARE  ALEMBIC LTD  WYETH LTD  ELDER PHARMA  SUVEN LIFESCIENCES  

Compare LUPIN With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

LUPIN Announces Quarterly Results (1QFY20); Net Profit Up 49.3% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, LUPIN has posted a net profit of Rs 3 bn (up 49.3% YoY). Sales on the other hand came in at Rs 44 bn (up 14.6% YoY). Read on for a complete analysis of LUPIN's quarterly results.

LUPIN 2018-19 Annual Report Analysis (Annual Result Update)

Jul 18, 2019 | Updated on Jul 18, 2019

Here's an analysis of the annual report of LUPIN for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.

LUPIN Announces Quarterly Results (4QFY19); Net Profit Down 1.5% (Quarterly Result Update)

May 17, 2019 | Updated on May 17, 2019

For the quarter ended March 2019, LUPIN has posted a net profit of Rs 3 bn (down 1.5% YoY). Sales on the other hand came in at Rs 44 bn (up 77.8% YoY). Read on for a complete analysis of LUPIN's quarterly results.

LUPIN LTD Announces Quarterly Results (3QFY19); Net Profit Down 149.7% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, LUPIN LTD has posted a net profit of Rs 2 bn (down 149.7% YoY). Sales on the other hand came in at Rs 45 bn (up 78.0% YoY). Read on for a complete analysis of LUPIN LTD's quarterly results.

LUPIN LTD Announces Quarterly Results (2QFY19); Net Profit Down 31.1% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, LUPIN LTD has posted a net profit of Rs 3 bn (down 31.1% YoY). Sales on the other hand came in at Rs 40 bn (up 53.1% YoY). Read on for a complete analysis of LUPIN LTD's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

LUPIN SHARE PRICE


Sep 20, 2019 (Close)

TRACK LUPIN

COMPARE LUPIN WITH

MARKET STATS